Journal article
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Abstract
BACKGROUND: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial.
METHODS: REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24 countries. We …
Authors
Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez L-E; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC
Journal
The Lancet Neurology, Vol. 19, No. 7, pp. 582–590
Publisher
Elsevier
Publication Date
July 2020
DOI
10.1016/s1474-4422(20)30173-3
ISSN
1474-4422